Sarepta Therapeutics

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Sarepta reports robust earnings, poised for gene therapy milestone

Sarepta Therapeutics delivered strong financial performance in Q4 2022, driven by revenue growth and positive market reception of its RNA-based PMO therapies.
While facing challenges in managing expenses and navigating regulatory uncertainties, the company is strategically positioned to capitalize on growth opportunities in gene therapy and market expansion.
By focusing on innovation, operational readiness, and market access, Sarepta aims to secure a leading position in Duchenne muscular dystrophy treatment and drive sustainable revenue growth.

Sarepta Therapeutics exceeds Q1 revenue expectations, poised for growth

Sarepta Therapeutics delivered strong financial results in Q1 2023, exceeding expectations and showcasing market confidence in their growth trajectory.
The company's proactive approach to patient access, payer engagement, and therapy development highlights their commitment to addressing unmet medical needs and advancing innovative treatments.
While facing pricing challenges and regulatory decisions, Sarepta's focus on research, partnerships, and therapy expansion presents opportunities for sustained growth and impact.
With a robust pipeline, positive payer discussions, and ongoing studies, Sarepta is poised to make a significant difference in treating rare diseases and improving patient outcomes.

Sarepta Therapeutics excels in Q2 with ELEVIDYS approval and patient-focused strategies

Sarepta Therapeutics demonstrated strong performance in Q2 2023 with positive revenue growth and progress in clinical studies and commercial activities.
Despite challenges in administrative processes and label expansion, the company's focus on patient care and operational efficiency remains a key strength.
Opportunities lie in broadening therapy access, addressing limitations, and streamlining patient access post label expansion for enhanced market reach and treatment efficiency.

Sarepta Therapeutics excels in Q3 earnings, eyes label expansion

Sarepta Therapeutics delivered robust financial performance in Q3 2023, driven by the success of ELEVIDYS and PMOs. Despite challenges in regulatory processes and market competition, the company's strategic focus on label expansion and patient access presents significant growth opportunities.

Sarepta Therapeutics reports robust Q4 earnings and targets pipeline expansion

Sarepta Therapeutics delivered strong financial results in Q4 2023, showcasing revenue growth and profitability. Despite facing challenges such as potential margin declines and clarity issues, the company is well-positioned to capitalize on opportunities for pipeline advancement and expansion.

Sarepta Therapeutics excels in Q1 earnings, eyes label expansions

Sarepta Therapeutics delivered strong financial performance in Q1 2024, driven by robust revenue growth and steady demand for key products like ELEVIDYS.
The company's strategic focus on label expansions and innovative R&D efforts positions it well for future success in addressing unmet medical needs and driving market expansion.
While facing challenges in patient demographics and operational readiness, Sarepta remains well-capitalized and poised to capitalize on upcoming opportunities for growth and market leadership.

Sarepta Therapeutics reports robust Q2 revenue and eyes therapy expansion

Sarepta Therapeutics is experiencing strong revenue growth driven by ELEVIDYS, with a focus on patient outcomes and manufacturing capacity. Challenges include addressing bottlenecks and patient prioritization, while opportunities exist in therapy development and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Align Technology

Lattice Semiconductor

SolarEdge Technologies

Not all technology companies are the same. In fact, not all chipmakers are the same.

Is It Time to Buy the Nasdaq's 4 Worst-Performing October Stocks?

NEW YORK , Nov. 4, 2023 /PRNewswire/ -- WHY:  Rosen Law Firm, a global investor rights law firm, continues investigating potential securities claims on behalf of shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) resulting from allegations that Sarepta may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Sarepta securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SRPT

NEW YORK , Nov. 3, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT). Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

Sarepta's (SRPT) Q3 earnings and sales beat estimates on the back of strong sales for recently approved DMD gene therapy Elevidys.

Sarepta (SRPT) Q3 Loss Narrower Than Expected, Sales Beat

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the UBS Biopharma Conference on Thursday, Nov. 9, 2023 at 9:00 a.m. E.T. The fireside chat will be held at the Fontainebleau Miami Beach in Miami Beach, Fla. The presentation will be webcast live under the Events & Presentations section of the investor relations section of Sarept.

Sarepta Therapeutics to Present at the UBS Biopharma Conference

Sarepta Therapeutics, Inc. (NASDAQ:SRPT ) Q3 2023 Earnings Conference Call November 1, 2023 4:30 PM ET Company Participants Francesca Nolan - IR Director Douglas Ingram - President and CEO Louise Rodino-Klapac - EEVP, Chief Scientific Officer and Head of Research & Development Dallan Murray - EVP & Chief Customer Officer Ian Estepan - EVP & CFO Conference Call Participants Anupam Rama - JPMorgan Tazeen Ahmad - Bank of America Securities Gena Wang - Barclays Colin Bristow - UBS Brian Skorney - Baird Salveen Richter - Goldman Sachs Uy Ear - Mizuho Danielle Brill - Raymond James Ritu Baral - TD Cowen Mike Ulz - Morgan Stanley Tim Lugo - William Blair Gil Blum - Needham & Company Brian Abrahams - RBC Capital Jason Bouvier - Cantor Fitzgerald Joseph Schwartz - Leerink Partners Operator Good afternoon and welcome to the Sarepta Therapeutics Third Quarter 2023 Earnings Call. At this time, all participants are in listen-only mode.

Sarepta Therapeutics, Inc. (SRPT) Q3 2023 Earnings Call Transcript

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the third quarter 2023. “The third quarter was a defining moment for Sarepta. We launched ELEVIDYS, our fourth therapy and the first gene therapy for boys with Duchenne muscular dystrophy, we continued to drive great performance of our three PMOs and importantly, on a non-GAAP basis we have achieved profitability, placing u.

Sarepta Therapeutics Announces Third Quarter 2023 Financial Results and Recent Corporate Developments

Sarepta Therapeutics' gene therapy, Elevidys, faces an uphill regulatory journey, analysts said Tuesday on mixed test results.

Sarepta Crashes 39% After Its Gene Therapy Flops Its Biggest-Ever Test

EMBARK study mixed results: Elevidys missed primary endpoint but showed strong secondary outcomes, affecting FDA approval calculus for DMD. Strong financials: Q2 revenue growth and a 33.6-month cash runway diminish near-term financing risk; operational loss reduced YoY. Investment recommendation: Maintain a "Buy", albeit speculative, position, but prepare for possible regulatory delays; diversification advised to hedge risk.

Sarepta's Elevidys: Secondary Outcomes Hold Regulatory Promise

Sarepta's DMD drug Elevidys failed to meet the primary endpoint in a phase 3 study. However, the company plans to pursue an expanded label for the drug anyway.

Why Sarepta Therapeutics Stock Is Crashing Today

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, continues investigating potential securities claims on behalf of shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) resulting from allegations that Sarepta may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Sarepta securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A LEADING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – SRPT

Sarepta Therapeutics (NASDAQ: SRPT ) stock is taking a beating on Tuesday after the biopharmaceutical company announced results from a Phase 3 clinical trial. That clinical trial covers the use of ELEVIDYS as a treatment for patients ages four to seven suffering from Duchenne muscular dystrophy.

Why Is Sarepta Therapeutics (SRPT) Stock Down 47% Today?

Sarepta Therapeutics shares fell over 42% in premarket trading on Tuesday, after its gene therapy for a progressive muscle-wasting disorder failed to meet the main goal in a trial that was key to the treatment securing full U.S. approval.

Sarepta shares slump as muscle disorder therapy fails to meet key trial goal

Sarepta Therapeutics Inc. shares SRPT, +0.77% dropped more than 40% premarket on Tuesday after the company said a trial of its gene therapy for Duchenne muscular dystrophy fell short of its main goal.

Sarepta Therapeutics shares plunge as gene therapy trial falls short of primary goal

In a gene therapy study for patients with Duchenne muscular dystrophy, the primary endpoint was not met.

Sarepta Stock Sinks on Mixed Gene Therapy Results

Sarepta unveiled mixed results late Monday for a gene therapy that targets a muscle-wasting disease in boys. SRPT stock was halted.

Sarepta Therapeutics Stock Halted After Unveiling Mixed Results For Its First Gene Therapy

Sarepta Therapeutics' gene therapy to treat Duchenne muscular dystrophy failed to reach statistical significance in a late-stage trial, the company reported after the bell on Monday.

Sarepta's gene therapy fails to meet primary goal in rare muscular dystrophy trial

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics announces the topline results from EMBARK, a global pivotal study of ELEVIDYS gene therapy for Duchenne muscular dystrophy.

Sarepta Therapeutics Announces Topline Results from EMBARK, a Global Pivotal Study of ELEVIDYS Gene Therapy for Duchenne Muscular Dystrophy

Capricor Therapeutics

Recent dip in CAPR's stock price following update on regulatory pathway for CAP-1002 and cash raise represents a buying opportunity. Completion of enrollment of Cohort A of ongoing Phase 3 trial of CAP-1002 is expected in Q4 2023, topline results in Q4 2024 and BLA submission in 2025. Risks for CAPR include; failure of ongoing Phase 3 trial, regulatory delays and need for more dilutive cash raise by the end of 2024.

Capricor Therapeutics, Sarepta Therapeutics: A Promising Clinical-Stage Biotech And A Commercial-Stage Leader In Duchenne Muscular Dystrophy

Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sarepta Therapeutics (SRPT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2023 financial results after the Nasdaq Global Market closes on Wednesday, Nov. 1, 2023. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its third quarter 2023 financial results. The event will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sar.

Sarepta Therapeutics to Announce Third Quarter 2023 Financial Results

The consensus price target hints at a 50.6% upside potential for Sarepta Therapeutics (SRPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Believe Sarepta Therapeutics (SRPT) Could Rally 50.6%: Here's is How to Trade

Biogen

bluebird bio

BioMarin Pharmaceutical

CRISPR Therapeutics

Editas Medicine

Intellia Therapeutics

Novartis

Regeneron Pharmaceuticals

Solid Biosciences

It's not often that you see a company whose main product comes with a price tag of over $2 million, but that's the case with biotechs BioMarin Pharmaceutical NASDAQ: BMRN and Sarepta Therapeutics NASDAQ: SRPT, which are developing gene therapies. ‘

Are Gene Therapy Stocks The Market's Next Big Winners?

Shopify

Sarepta Therapeutics is successfully developing treatments for a rare and devastating disease. Shopify's recent moves should make it even stronger in the fast-growing e-commerce industry.

2 Top Growth Stocks to Buy With $500

Sarepta Therapeutics, Inc. results from pivotal EMBARK study, using ELEVIDYS for the treatment of ambulatory DMD patients between ages 4 to 7 expected in Q4 of 2023. The primary endpoint being met in EMBARK study would allow label expansion for all ambulatory DMD patients, regardless of age. Another expansion opportunity for ELEVIDYS would be the targeting of non-ambulatory DMD patients; This might be possible with a successful outcome from the ENVISION study.

News for Sarepta Therapeutics Stock (SRPT)